The FDA Regulatory Architecture: A Mental Model for Bankers

Introduction

Healthcare bankers do not need to be regulatory experts. But they need a working mental model of how the FDA creates value through regulation, because the regulatory pathway a product follows determines its development cost, time to market, competitive moat, and ultimately its place in the valuation lifecycle. This article provides that mental model by mapping the three major product categories and their fundamentally different approval pathways.

The FDA organizes healthcare product regulation through three primary centers, each overseeing a distinct product category with its own rules, timelines, and competitive dynamics.

CDER, CBER, and CDRH

CDER (Center for Drug Evaluation and Research) reviews small molecule drugs and some therapeutic biologics through the New Drug Application (NDA) process. CBER (Center for Biologics Evaluation and Research) reviews complex biologics (vaccines, blood products, gene therapies, cell therapies) through the Biologics License Application (BLA). CDRH (Center for Devices and Radiological Health) reviews medical devices through 510(k), PMA, or De Novo pathways. Understanding which center reviews a product tells you the regulatory timeline, cost structure, and competitive protection framework.

The drug approval process is the most familiar regulatory framework in healthcare banking because it drives the largest volume of M&A. A new drug moves through a multi-phase clinical development process:

Preclinical (2-4 years): Laboratory and animal studies to establish safety and potential efficacy. The company files an Investigational New Drug (IND) application to begin human testing.

Phase I (6-12 months): Small trials (20-80 patients) focused primarily on safety, dosing, and pharmacokinetics. Phase I trials rarely fail on safety alone, with approximately 60-65% of drugs advancing.

Phase II (1-2 years): Larger trials (100-300 patients) testing efficacy and dose-response. This is the highest-attrition phase, with only 30-35% of drugs advancing. Phase II is where most drugs fail because efficacy in a controlled setting does not translate to larger populations.

Phase III (2-4 years): Large-scale trials (1,000-5,000+ patients) designed to confirm efficacy and monitor side effects. These trials cost $50-150 million+ each and must hit pre-specified primary endpoints with statistical significance. Roughly 55-65% of drugs that enter Phase III receive approval.

FDA Review (10-12 months standard, 6-8 months priority): After the company submits the NDA with all clinical data, FDA reviews and issues an approval, Complete Response Letter (rejection), or request for additional information.

Biologics (large, complex molecules produced by living cells) follow a similar clinical development pathway but with a critical difference in competitive protection. The Biologics Price Competition and Innovation Act (BPCIA) grants 12 years of regulatory exclusivity from first licensure, compared to 5 years for small molecule NCEs.

This extended exclusivity exists because biosimilars are fundamentally harder to produce than generic drugs. A generic drug is chemically identical to the original; a biosimilar is "highly similar" but not identical because of the complexity of biological manufacturing. This manufacturing complexity creates additional competitive barriers beyond the regulatory exclusivity period.

Device regulation operates on fundamentally different principles than drug regulation. Devices are classified into three risk categories (Class I, II, III), and the regulatory pathway depends on the classification.

The 510(k) Pathway

The 510(k) substantial equivalence pathway accounts for approximately 85% of device clearances. A manufacturer demonstrates that its new device is "substantially equivalent" to an already-marketed predicate device. The process typically costs $50K-$150K and takes 3-6 months.

From a banking perspective, 510(k) clearance is fast and cheap but creates a weaker competitive moat. Because the cleared device can itself serve as a predicate for future competitors, the barrier to entry is relatively low. This means 510(k)-cleared devices compete more on commercial execution (sales force, physician relationships, hospital contracts) than on regulatory exclusivity.

The PMA Pathway

Pre-Market Approval (PMA) is required for Class III (highest risk) devices and demands full clinical evidence of safety and efficacy, similar to the drug approval process. PMAs cost $75 million or more and take 3-5 years. The competitive protection is stronger: each PMA is device-specific, and competitors must file their own PMA with independent clinical data.

De Novo Classification

A regulatory pathway for novel devices that have no legally marketed predicate (making 510(k) impossible) but are not high-risk enough to require PMA. De Novo creates a new regulatory classification and allows the device to serve as a predicate for future 510(k) submissions. This pathway has become increasingly important for AI/ML-enabled medical devices, digital health tools, and other novel technologies. Over 1,250 FDA-authorized AI/ML devices have been cleared through various pathways.

Why Device Regulatory Pathway Matters for Valuation

The regulatory pathway directly affects a device company's competitive position and therefore its valuation multiple. A device cleared through 510(k) faces easier competitive entry and commands lower revenue multiples (2-4x). A device approved through PMA has a stronger moat and commands higher multiples (4-8x revenue). Healthcare bankers assess the regulatory pathway when building medtech comps because it is a primary determinant of competitive sustainability.

The FDA architecture described here is the foundation for understanding expedited pathways (which modify the standard timelines), patent vs. regulatory exclusivity (which determines competitive moat duration), and the sub-sector-specific regulatory dynamics covered in Sections 3-7 of this guide.